Clark, V.
University of Florida
4 papers on CoChatORCID 0000-0001-6719-3634
Most cited papers
- Verified
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 1,035
- Verified
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology
Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 199
- Verified
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology
Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors
Cited by 191
- Verified
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid: Pilot study: fenofibrate with UDCA for primary biliary cirrhosis
Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 186
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free